Skip to main content
. 2017 Apr 3;108(3):448–454. doi: 10.1111/cas.13150

Figure 4.

Figure 4

Increased cirExo‐TRPC5 level after chemotherapy predicted acquired chemoresistance. Metastatic breast cancer patients with a cirExo‐TRPC5 increase of more than 1.09 times (n = 36) after the first 2 chemotherapy cycles showed a significantly shorter progression free survival than patients with a cirExo‐TRPC5 increase of not more than 1.09 times (n = 55) (log‐rank, = 0.0042).